Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.).

Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV.

Emerg Infect Dis. 2013 Jul;19(7):1074-83. doi: 10.3201/eid1907.121830.

2.
3.

Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era.

Gertz RE Jr, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, Jorgensen JH, Carvalho Mda G, Beall BW; Active Bacterial Core Surveillance Team.

J Infect Dis. 2010 Mar;201(5):770-5.

5.

Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.

Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, Purdy J, Paradiso P, File TM Jr.

J Infect Dis. 2013 Dec 1;208(11):1813-20. doi: 10.1093/infdis/jit506. Epub 2013 Oct 2.

6.

Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995-2009.

Ho PL, Chiu SS, Ang I, Lau YL.

Vaccine. 2011 Apr 12;29(17):3270-5. doi: 10.1016/j.vaccine.2011.02.025. Epub 2011 Feb 23.

PMID:
21352937
7.

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG; Toronto Bacterial Diseases Network; Canadian Public Health Laboratory Network.

Can J Microbiol. 2013 Dec;59(12):778-88. doi: 10.1139/cjm-2013-0614. Epub 2013 Oct 21.

PMID:
24313450
8.

Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.

Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV.

Antimicrob Agents Chemother. 2014 Nov;58(11):6484-9. doi: 10.1128/AAC.03344-14. Epub 2014 Aug 18.

9.

Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.

Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.

Pediatr Infect Dis J. 2013 Jun;32(6):604-9. doi: 10.1097/INF.0b013e318287fe0d.

PMID:
23348816
10.

Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010.

Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Shane A, Zhanel GG, Tyrrell GJ, Gilmour MW; Toronto Invasive Bacterial Diseases Network; Canadian Public Health Laboratory Network.

Can J Microbiol. 2012 Aug;58(8):1008-17. doi: 10.1139/w2012-073. Epub 2012 Jul 24.

PMID:
22827750
11.

Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L.

BMC Infect Dis. 2012 Sep 7;12:207. doi: 10.1186/1471-2334-12-207. Review.

12.

Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2010 Apr;300(4):237-47. doi: 10.1016/j.ijmm.2009.05.005. Epub 2009 Jul 14.

PMID:
19604721
13.

Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.

Watson M, Bayley K, Bell JM, Gilbert GL, Hogg G, Keil AD, Krause V, Murphy D, Roche P, Smith HV, Stewart MG, Stylianopoulos J, Turnidge J.

Commun Dis Intell Q Rep. 2003;27(4):478-87.

PMID:
15508501
14.

Non-susceptibility trends and serotype coverage by conjugate pneumococcal vaccines in a Tunisian paediatric population: a 10-year study.

Charfi F, Smaoui H, Kechrid A.

Vaccine. 2012 Dec 31;30 Suppl 6:G18-24. doi: 10.1016/j.vaccine.2012.07.017.

PMID:
23228353
15.

Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.

Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO Jr.

Pediatr Infect Dis J. 2013 Mar;32(3):203-7. doi: 10.1097/INF.0b013e318275614b.

PMID:
23558320
16.
17.

Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012.

Aguiar SI, Brito MJ, Horacio AN, Lopes JP, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections; Portuguese Study Group of Invasive Pneumococcal Disease of the Paediatric Infectious Disease Society.

Euro Surveill. 2014 Mar 27;19(12):20750.

18.

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA, Jones RN.

Diagn Microbiol Infect Dis. 2014 Sep;80(1):19-25. doi: 10.1016/j.diagmicrobio.2014.05.020. Epub 2014 May 24.

PMID:
24974272
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk